NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ — Recent
findings published in the scientific journal Leukemia
showed that when combined with standard anti-leukemia agents, the
biological activity of LeukotheraTM, a drug candidate
under development by Actinobac Biomed, Inc., showed synergistic
The outcome of these in vitro experiments
demonstrated that combining LeukotheraTM with
such widely employed drugs as etoposide, mitoxantrone,
daunorubicin, busulfan and imatinib killed leukemia cells much more
effectively than when the agents were used alone.
LeukotheraTM is a natural biologic agent that
specifically targets malignant and/or inflammatory white blood
cells involved in disease.
Dr. Scott Kachlany, founder of Actinobac Biomed, explained.
“Drug combination therapies for cancer are now frequently
considered by oncologists due to their many advantages, which
include the possibility of reducing doses of toxic chemotherapeutic
agents and a lower chance of developing drug resistance,” he said.
“The biological mechanism of LeukotheraTM differs
from that of other cancer drugs so including it to blood cancer
treatment protocols may be a highly effective strategy.”
Actinobac Biomed, Inc. was founded in 2009 with financial
backing from Foundation Venture Capital Group, LLC, to develop
commercial products based upon technology developed at the
University of Medicine and Dentistry of New Jersey. The
company has exclusively licensed the rights to develop
LeukotheraTM as a therapeutic agent for the treatment of
hematologic malignancies, autoimmune and inflammatory diseases and
“We provided early seed funding to Actinobac because we are